Blood: Hemostasis, Blood Typing, and Transfusion in Human Anatomy & Physiology II

Blood: Hemostasis, Blood Typing, and Transfusion

Introduction

Blood is a vital connective tissue responsible for transport, regulation, and protection within the human body. This study guide focuses on the mechanisms of hemostasis, the process of blood clotting, and the principles of blood typing and transfusion compatibility, as covered in a college-level Anatomy & Physiology II course.

Hemostasis

Overview of Hemostasis

Hemostasis is the physiological process that stops bleeding at the site of an injury. It involves a rapid, localized response to blood vessel damage and requires the coordinated action of clotting factors, platelets, and substances released by injured tissues.

• Purpose: Prevent excessive blood loss following vascular injury.

• Key Components: Platelets, clotting factors (procoagulants), and vascular endothelium.

• Three Major Steps:

  1. Vascular spasm

  2. Platelet plug formation

  3. Coagulation (blood clotting)

Step 1: Vascular Spasm

Vascular spasm is the immediate constriction of a damaged blood vessel to reduce blood flow and limit blood loss.

• Triggers:

  • Direct injury to vascular smooth muscle

  • Chemicals released by endothelial cells and platelets

  • Pain reflexes

• Effectiveness: Most effective in smaller blood vessels.

• Example: When a small artery is cut, the vessel constricts to minimize blood loss until further hemostatic mechanisms are activated.

Step 2: Platelet Plug Formation

Platelet plug formation is a positive feedback process where platelets adhere to exposed collagen fibers at the injury site, aggregate, and release chemical messengers to recruit more platelets.

• Sequence:

  1. Damage to endothelium exposes collagen fibers.

  2. Platelets adhere to collagen via plasma protein von Willebrand factor.

  3. Platelets become activated: swell, become spiked and sticky, and release chemical messengers (e.g., ADP, serotonin, thromboxane A2).

  4. More platelets are attracted, forming a temporary platelet plug.

• Clinical Relevance: Deficiency in von Willebrand factor leads to bleeding disorders (e.g., von Willebrand disease).

Step 3: Coagulation (Blood Clotting)

Coagulation reinforces the platelet plug with a mesh of fibrin threads, transforming blood from a liquid to a gel.

• Clotting Factors: Most are plasma proteins synthesized by the liver; vitamin K is required for synthesis of several factors.

• Phases of Coagulation:

  1. Phase 1: Formation of prothrombin activator via intrinsic and/or extrinsic pathways, both triggered by tissue damage and involving a cascade of procoagulants. Ends with activation of factor X.

  2. Phase 2: Prothrombin activator catalyzes conversion of prothrombin to thrombin.

  3. Phase 3: Thrombin converts soluble fibrinogen to insoluble fibrin, forming the structural basis of the clot. Thrombin (with Ca2+) also activates factor XIII, which cross-links and stabilizes the fibrin mesh.

• Key Equation:

  • $\text{Prothrombin} \xrightarrow{\text{Prothrombin Activator}} \text{Thrombin}$

  • $\text{Fibrinogen} \xrightarrow{\text{Thrombin}} \text{Fibrin}$

Clot Retraction and Vessel Repair

After a clot forms, it must be stabilized and eventually removed as the vessel heals.

• Clot Retraction: Platelet actin and myosin contract, pulling on fibrin strands and squeezing serum from the clot, drawing vessel edges together (occurs within 30–60 minutes).

• Vessel Repair: Platelet-derived growth factor (PDGF) stimulates smooth muscle and fibroblast proliferation; vascular endothelial growth factor (VEGF) stimulates endothelial cell regeneration.

Fibrinolysis

Fibrinolysis is the process of removing unneeded clots after healing. It begins within two days and continues until the clot is dissolved.

• Key Enzyme: Plasmin, which digests fibrin.

Disorders of Hemostasis

Thromboembolic Disorders

These disorders involve undesirable clot formation.

• Thrombus: A clot that develops and persists in an unbroken blood vessel, potentially blocking circulation and causing tissue death.

• Embolus: A thrombus that breaks away and floats in the bloodstream; can lodge in smaller vessels, causing embolism (e.g., pulmonary or cerebral emboli).

• Risk Factors: Atherosclerosis, inflammation, slow blood flow, immobility.

Anticoagulant Drugs

• Aspirin: Inhibits thromboxane A2 (antiprostaglandin), reducing platelet aggregation.

• Heparin: Used clinically to prevent clotting during and after cardiac procedures.

• Warfarin (Coumadin): Interferes with vitamin K action; used for patients at risk of atrial fibrillation.

Bleeding Disorders

• Thrombocytopenia: Deficiency of circulating platelets, leading to spontaneous bleeding and petechiae. Causes include bone marrow suppression or destruction.

• Hemophilia: Group of hereditary bleeding disorders caused by deficiencies in specific clotting factors.

  • Hemophilia A: Factor VIII deficiency (most common).

  • Hemophilia B: Factor IX deficiency.

  • Hemophilia C: Factor XI deficiency (milder form).

• Symptoms: Prolonged bleeding, especially into joints.

• Treatment: Plasma transfusions and injection of missing clotting factors.

Blood Typing and Transfusion

Human Blood Groups

Blood groups are determined by the presence or absence of specific antigens (agglutinogens) on the surface of red blood cells (RBCs). These antigens can trigger immune responses if foreign blood is transfused.

• ABO System: Based on the presence of A and/or B antigens.

• Rh System: Based on the presence (+) or absence (−) of the D antigen.

ABO Blood Types

Blood Type	Antigens on RBC	Antibodies in Plasma	Can Receive From	Can Donate To
A	A	Anti-B	A, O	A, AB
B	B	Anti-A	B, O	B, AB
AB	A and B	None	A, B, AB, O (universal recipient)	AB
O	None	Anti-A, Anti-B	O	A, B, AB, O (universal donor)

Rh Blood Groups

• Rh-positive (Rh+): D antigen present (about 85% of Americans).

• Rh-negative (Rh−): D antigen absent; anti-Rh antibodies form only after exposure to Rh+ blood.

Transfusion Reactions

Transfusion of incompatible blood can cause agglutination and destruction of donor RBCs, leading to potentially fatal reactions.

• Symptoms: Fever, chills, low blood pressure, rapid heartbeat, nausea, vomiting.

• Treatment: Prevent kidney damage with fluids and diuretics to remove free hemoglobin.

Hemolytic Disease of the Newborn (HDN)

HDN occurs when an Rh− mother carries an Rh+ fetus, leading to maternal anti-Rh antibodies attacking fetal RBCs in subsequent pregnancies.

• Prevention: Administration of Rho(D) immune globulin (RhoGAM) to Rh− mothers during and after pregnancy.

Restoring Blood Volume

• Immediate Replacement: Normal saline or multiple-electrolyte solutions (e.g., Ringer's solution) mimic plasma electrolyte composition.

• Plasma Expanders: Substances like purified human serum albumin, hetastarch, and dextran mimic osmotic properties of albumin but may have complications.

Diagnostic Blood Tests

• Hematocrit: Measures the percentage of RBCs in blood; used to diagnose anemia.

• Blood Glucose Tests: Used to diagnose diabetes mellitus.

• Microscopic Examination: Reveals variations in RBC size and shape, indicating anemia or other disorders.

• Differential WBC Count: Assesses types and numbers of white blood cells.

• Prothrombin Time and Platelet Counts: Assess hemostasis and clotting ability.

• Blood Chemistry Profile: Evaluates liver and kidney function.

• Complete Blood Count (CBC): Provides a comprehensive overview of formed elements, hematocrit, and hemoglobin levels.

Additional info: This guide expands on the provided notes with definitions, clinical context, and a summary table for ABO blood types, as is standard in Anatomy & Physiology textbooks.